NCT07593391 NNZ-2591 Phelan-McDermid Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Move from a broad disease map to a decision-ready trial dossier. This focused report examines NCT07593391—An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.
MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.
Why NCT07593391 is a hot trial to watch
Phelan-McDermid Syndrome is no longer one homogeneous development market. The most consequential programs increasingly compete through a specific mechanism, biomarker, treatment line, delivery strategy or endpoint architecture. NCT07593391 is notable because it tests NNZ-2591 in a Phase 3 design with Long-term safety and tolerability of NNZ-2591 as assessed by the incidence of adverse events across participants as a primary decision variable. The wider PatSnap topic query returned 9 trial records and 5 result records, so differentiation depends on evidence quality rather than activity alone.
PatSnap Clinical Trials MCP makes the protocol fields machine-readable, while the companion asset and organization servers add mechanism and sponsor context.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07593391 |
| Official title | An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome |
| Phase / status | Phase 3 / Recruiting |
| Intervention | NNZ-2591 |
| Sponsor | Neuren Pharmaceuticals Ltd. |
| Geography | United States |
| Enrollment | 180 |
| Primary endpoint | Long-term safety and tolerability of NNZ-2591 as assessed by the incidence of adverse events across participants |
| Endpoint time frame | Baseline through Safety Follow-Up (Month 12) |
| Primary completion | 2028-10-29 |
| Study completion | 2028-11-12 |
Design and endpoint interpretation
The design should be read as an evidence architecture, not just a phase label. The primary endpoint—Long-term safety and tolerability of NNZ-2591 as assessed by the incidence of adverse events across participants—determines what uncertainty this study can resolve. The reported time frame is Baseline through Safety Follow-Up (Month 12). Enrollment of 180 participants and geography in United States shape statistical precision, operational risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.
Benchmark readouts in the same clinical field
- NNZ-2591 in Children and Adolescents With Phelan-McDermid Syndrome (Phase 2): TEAE = NNZ-2591 was well tolerated; most treatment-emergent adverse events were mild to moderate .
- An Open Label Trial of Growth Hormone in Children and Adolescents With Phelan-McDermid Syndrome Targeting Social Withdrawal (Phase 2): Irritability baseline(Mean) = 10.31 score on a scale (Standard Deviation, 7.6); -; -.
- Neuren Phase 2 trial shows significant improvements in Phelan-McDermid syndrome (Phase 2): TESAE(gastroenteritis) = 1 pts .
These result records are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, line of therapy, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.
Build a living trial monitor: connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset context: NNZ-2591 (Phase 3; IGF-1).
Company & Deal Intelligence context: Neuren Pharmaceuticals Ltd. (NEU) — http://www.neurenpharma.com.
The sponsor profile matters because a trial's strategic value depends on more than scientific rationale. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes that connect biological activity with function, symptoms, survival or treatment burden.
- Sequencing evidence: randomized data after the most relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world care settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety monitoring or durability.
What to monitor next
Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.
Bottom line
NCT07593391 is a focused lens on Phelan-McDermid Syndrome development. Its value will be determined by whether NNZ-2591 can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from topic-level benchmark readouts.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
